Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dead stock

<< Previous

Bullboard Posts

Next >>

Comment by muto412on Aug 12, 2021 10:57pm

275 Views

Post# 33699119

RE:Dead stock

Lower dose trial finished by end of 22. Phase 3 starting in 2023. Not ideal, but only pushed out 1-1.5 years max.

Nasdaq may still happen after phase 2 lowest dose de-risk.

I agree, Dan HAS to go. Time to bring on someone with experience leading a small biotech to the finish line. I have supported him all along as I believed the strategy was good. But he is now at the helm while 2 trials (phase 1 and AME) have faced issues. IMO installing a new CEO might instill confidence in institutional investors...

for context - I've been here since 2016 and am long. Lost a significant amount of $$ this week, but still believe in the product.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity